no adverse side effects were reported.
-- PS33/THU/01 -- Pooled results from two separate studies led by Profs.
Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory
blood pressure monitoring demonstrated that RESPeRATE benefits
uncontrolled-hypertension sufferers. The analysis demonstrated a
clinically significant blood pressure reduction throughout both daytime
and nighttime. RESPeRATE was also found to independently reduce high
values of a risk-associated arterial property (S-D slope/AASI) derived
from the relationship between systolic and diastolic pressures.
-- PS34/MON/08 -- Data analysis led by Dr. Benjamin Gavish, chief
scientific officer, InterCure, Ltd., of a study performed in Italy,
conducted by Prof. Gianfranco Parati, explored, for the first time, the
linear relationships between systolic and diastolic blood pressure from
beat-to-beat measurements. The derived risk-related parameters (S-D
slope and AASI) are acutely influenced by breathing patterns and neck
-- PS34/MON/18 -- An Israeli study, conducted by Dr. Iddo Ben-Dov and
Prof. Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin
Gavish, concluded that the ratio of systolic to diastolic blood
pressure variability is shown to be a blood pressure-independent
predictor of mortality, associated with the linear relationship between
systolic and diastolic pressures.
-- PS18/WED/58 -- An Italian, randomized controlled study, led by Prof. G.
Parati from the University of Milan-Bicocca concluded that device-
guided paced breathing at home is feasible and improves prognostically
relevant clinical and instrumental parameters in heart failure
patients. It is recommended as an additiona
|SOURCE InterCure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved